SCHEMBL21479785

SCHEMBL21479785

CC1(C)O[C@@H]2[C@@H](NC(=O)C(F)(F)F)[C@@H]3OC[C@](COCCOCCOCCOCCN)(O3)[C@@H]2O1

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ASGR1 P07306 11/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063862 1.00 ASGR1 (0.44) ASGR1
SCHEMBL26879967 0.98 ASGR1 (0.46) ASGR1
SCHEMBL21479699 0.87 ASGR1 (0.42) ASGR1
SCHEMBL18968191 0.86 ASGR1 (0.42) ASGR1
SCHEMBL26902129 0.83 CA2 (0.31) ASGR1
SCHEMBL23346073 0.82 ASGR1 (0.62) ASGR1
SCHEMBL26879913 0.81 ASGR1 (0.65) ASGR1
SCHEMBL24256177 0.81 ASGR1 (0.65) ASGR1
SCHEMBL17256429 0.79 ASGR1 (0.67) ASGR1
SCHEMBL17256431 0.79 ASGR1 (0.56) ASGR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767301-B2 Bi-functional molecules to degrade circulating proteins YALE UNIVERSITY (US) 2023-09-26 — — US disclosed
US-11767301-B2 Bi-functional molecules to degrade circulating proteins YALE UNIVERSITY (US) 2023-09-26 — — US disclosed
WO-2023178179-A2 BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
WO-2023178202-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 — — US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 — — US disclosed
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 — — EP disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
WO-2021155317-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2021-08-05 — — WO disclosed
US-20210145974-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins YALE UNIVERSITY 2021-05-20 — — US disclosed
US-20210139436-A1 Bi-functional Molecules to Degrade Circulating Proteins YALE UNIVERSITY 2021-05-13 — — US disclosed
WO-2019199634-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS YALE UNIVERSITY (US) 2019-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767301-B2 Bi-functional molecules to degrade circulating proteins MIF, ASGR1, FCGR2A ASGR1 2/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A ASGR1 1/4885
US-20210145974-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR3B ASGR1 1/4885
US-20210139436-A1 Bi-functional Molecules to Degrade Circulating Proteins MIF, ASGR1, FCGR2A ASGR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback